Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
VRTX
$463.86
$-5.82
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Next Earnings
2026-01-11
Beta
0.314
Average Volume
1365859
Market Cap
119037056647
Last Dividend
0
CIK
0000875320
ISIN
US92532F1003
CUSIP
92532F100
CEO
Reshma Kewalramani
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
6100
IPO Date
1991-07-24
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| The Best Stocks to Invest $50,000 in Right Now | Alphabet is playing to win in the AI market. Micron is arguably the biggest AI bargain around. | The Motley Fool | 2026-01-11 05:41:00 |
| Ourania Tatsis Sells 4,500 Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) Stock | Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX - Get Free Report) EVP Ourania Tatsis sold 4,500 shares of the firm's stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $474.99, for a total value of $2,137,455.00. Following the completion of the transaction, the executive vice president directly owned 42,293 shares | Defense World | 2026-01-11 04:54:43 |
| Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Consensus Rating of “Moderate Buy” from Analysts | Shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twenty-seven analysts that are covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating on | Defense World | 2026-01-11 01:40:51 |
| HB Wealth Management LLC Cuts Stake in Vertex Pharmaceuticals Incorporated $VRTX | HB Wealth Management LLC reduced its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 18.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,680 shares of the pharmaceutical company's stock after selling 1,903 shares during the period. HB Wealth | Defense World | 2026-01-10 05:00:43 |
| Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts | In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $463.86, indicating a -1.24% shift from the previous trading day. | Zacks Investment Research | 2026-01-09 18:50:37 |
| Duncker Streett & Co. Inc. Has $922,000 Stake in Vertex Pharmaceuticals Incorporated $VRTX | Duncker Streett and Co. Inc. lessened its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 69.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,355 shares of the pharmaceutical company's stock after selling 5,377 shares during the period. Duncker Streett | Defense World | 2026-01-09 04:52:45 |
| Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know | Vertex Pharmaceuticals (VRTX) reached $469.68 at the closing of the latest trading day, reflecting a -2.99% change compared to its last close. | Zacks Investment Research | 2026-01-08 19:02:12 |
| Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know | Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. | Zacks Investment Research | 2026-01-07 10:01:27 |
| Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Cerity Partners LLC | Cerity Partners LLC decreased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 1.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 258,808 shares of the pharmaceutical company's stock after selling 4,884 shares during the quarter. Cerity Partners LLC owned approximately 0.10% | Defense World | 2026-01-07 06:38:42 |
| Galvin Gaustad & Stein LLC Purchases 10,252 Shares of Vertex Pharmaceuticals Incorporated $VRTX | Galvin Gaustad and Stein LLC boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 44.8% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,142 shares of the pharmaceutical company's stock after acquiring an additional 10,252 shares during the quarter. | Defense World | 2026-01-07 05:22:57 |
| My 10 Top Stocks to Buy to Start the New Year Off Right | This selection of stocks offers interesting buys throughout industries -- from tech to healthcare. Many of these players are trading at bargain levels. | The Motley Fool | 2026-01-05 20:15:00 |
| Generali Asset Management SPA SGR Acquires 6,942 Shares of Vertex Pharmaceuticals Incorporated $VRTX | Generali Asset Management SPA SGR lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 41.8% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 23,569 shares of the pharmaceutical company's stock after acquiring an additional 6,942 shares during the period. Generali Asset Management SPA | Defense World | 2026-01-02 05:46:43 |
| The Best Stocks to Invest $1,000 in to Start the New Year Off Right | Alphabet should continue to benefit from a strong AI tailwind in 2026. Vertex Pharmaceuticals has several growth drivers in the new year. | The Motley Fool | 2026-01-01 05:45:00 |
| Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Momentum Stock | Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. | Zacks Investment Research | 2025-12-30 10:50:19 |
| 2 Growth Stocks to Buy For 2026 and Beyond | Vertex could have several catalysts in 2026, helping it set a strong foundation for the future. DexCom is expanding its addressable market in order to help deal with some current challenges. | The Motley Fool | 2025-12-30 08:00:00 |
| 3 Supercharged Growth Stocks to Buy and Hold Into the 2030s | Amazon's profitability underscores the success of established and emerging growth sources. Vertex Pharmaceuticals is launching several new products, and more approvals could be around the corner. | The Motley Fool | 2025-12-28 13:13:00 |
| Forget Moderna Stock, This is a Much Better Buy | Moderna stock soared in the early stages of the pandemic, then struggled -- but in recent times, it's been on the rise. This other biotech has proven itself as a long-term winner. | The Motley Fool | 2025-12-27 10:10:00 |
| Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Founders Financial Securities LLC | Founders Financial Securities LLC boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 154.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,942 shares of the pharmaceutical company's stock after acquiring an additional 1,787 shares during the period. Founders Financial Securities LLC's | Defense World | 2025-12-25 04:48:48 |
| Alpine Woods Capital Investors LLC Sells 1,173 Shares of Vertex Pharmaceuticals Incorporated $VRTX | Alpine Woods Capital Investors LLC decreased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 21.0% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,421 shares of the pharmaceutical company's stock after selling 1,173 shares during the | Defense World | 2025-12-25 03:18:49 |
| Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It | Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store. | Zacks Investment Research | 2025-12-23 10:00:50 |
| Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12 | BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on. | Business Wire | 2025-12-22 16:00:00 |
| Vanguard Health Care Fund's Strategic Moves: Spotlight on AbbVie Inc | Exploring the Fund's Recent Portfolio Adjustments Vanguard Health Care Fund (Trades, Portfolio) recently submitted its N-PORT filing for the third quarter of 2 | GuruFocus | 2025-12-19 16:01:00 |
| Best Defensive Stocks To Balance Tech Sector Volatility | December's mixed performance for tech may be an early signal that leadership is narrowing, especially among the value-stretched stocks. Investors looking forward to 2026 may find better risk-adjusted opportunities in defensive sectors with select growth drivers. Rather than relying solely on traditional names, this article digs deeper into Quant Strong Buys that combine durable cash flows, essential services, and key growth metrics. | Seeking Alpha | 2025-12-18 08:30:00 |
| Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note | In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $449.52, denoting a -1.2% move from the preceding trading day. | Zacks Investment Research | 2025-12-17 18:51:17 |
| Graphene Investments SAS Boosts Stake in Vertex Pharmaceuticals Incorporated $VRTX | Graphene Investments SAS increased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 22.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,300 shares of the pharmaceutical company's stock after buying an additional 1,500 shares during the | Defense World | 2025-12-17 06:14:42 |
| Corient Private Wealth LLC Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX | Corient Private Wealth LLC reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 3.5% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 102,816 shares of the pharmaceutical company's stock after selling 3,734 shares during the | Defense World | 2025-12-17 04:56:45 |
| Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Average Rating of “Moderate Buy” from Analysts | Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twenty-eight analysts that are currently covering the stock, MarketBeat reports. Ten research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to | Defense World | 2025-12-17 01:58:52 |
| 12 Days of Investing: My Top 12 Stocks to Buy Before 2026 | There are only 12 investing days left in 2025. Now is a great time to load up on stocks that may win next year -- and over time. | The Motley Fool | 2025-12-15 11:10:00 |
| Castleark Management LLC Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX | Castleark Management LLC trimmed its stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 98.4% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 730 shares of the pharmaceutical company's stock after selling 46,309 shares during the period. Castleark Management LLC's | Defense World | 2025-12-15 04:06:51 |
| Ameriprise Financial Inc. Sells 54,107 Shares of Vertex Pharmaceuticals Incorporated $VRTX | Ameriprise Financial Inc. lowered its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 2.4% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 2,181,362 shares of the pharmaceutical company's stock after selling 54,107 shares during the period. Ameriprise Financial Inc. owned about 0.85% of | Defense World | 2025-12-13 04:10:50 |
| Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know | Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. | Zacks Investment Research | 2025-12-12 10:00:33 |
| 3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term | Apple's fiercely loyal customer base gives it a built-in market for any new devices it might launch in the future. MercadoLibre is positioned to grow rapidly in the Latin America e-commerce and fintech markets. | The Motley Fool | 2025-12-12 02:44:00 |
| Why Vertex Pharmaceuticals (VRTX) is a Top Momentum Stock for the Long-Term | Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. | Zacks Investment Research | 2025-12-08 10:51:07 |
| Disney, Nu Holdings, Phillips 66 And A Health Care Stock On CNBC's 'Final Trades' | Nu Holdings, Phillips 66, Vertex Pharmaceuticals and Disney get shoutouts on CNBC's "Halftime Report Final Trades." | Benzinga | 2025-12-08 10:44:39 |
| Federated Hermes Inc. Acquires 23,726 Shares of Vertex Pharmaceuticals Incorporated $VRTX | Federated Hermes Inc. boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 13.9% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 193,959 shares of the pharmaceutical company's stock after buying an additional 23,726 shares during the quarter. Federated Hermes Inc. | Defense World | 2025-12-08 05:03:18 |
| Cerity Partners LLC Purchases 10,768 Shares of Vertex Pharmaceuticals Incorporated $VRTX | Cerity Partners LLC boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 4.3% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 263,692 shares of the pharmaceutical company's stock after purchasing an additional 10,768 shares during the period. Cerity Partners LLC owned about 0.10% of | Defense World | 2025-12-07 04:21:06 |
| Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals? | Vertex Pharmaceuticals is the worldwide leader in cystic fibrosis treatment -- and its drugs have generated blockbuster revenue. The company has expanded into other therapeutic areas in recent years and has won approval for treatments for blood disorders and pain management. | The Motley Fool | 2025-12-06 19:15:00 |
| Vertex's gene therapy shows promise in younger children with blood disorders | Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease to be free of painful events and allowed those with another blood disorder that requires frequent blood transfusions to be transfusion-free for at least 12 consecutive months. | Reuters | 2025-12-06 07:04:42 |
| Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions | BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with seve. | Business Wire | 2025-12-06 07:01:00 |
| 1 Reason I'll Never Sell Vertex Pharmaceuticals Stock | Vertex Pharmaceuticals dominates the cystic fibrosis treatment market and recently has expanded into other therapeutic areas. The biotech predicts full-year 2025 revenue of as much as $12 billion. | The Motley Fool | 2025-12-04 15:10:00 |
| Groupe la Francaise Raises Holdings in Vertex Pharmaceuticals Incorporated $VRTX | Groupe la Francaise boosted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 25.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,989 shares of the pharmaceutical company's stock after buying an additional 1,625 shares | Defense World | 2025-12-04 05:14:42 |
| Fisher Asset Management LLC Has $11.47 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX | Fisher Asset Management LLC cut its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 16.0% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 25,755 shares of the pharmaceutical company's stock after selling 4,914 shares during the period. Fisher Asset Management | Defense World | 2025-12-04 04:40:49 |
| Why Is Vertex (VRTX) Up 2.7% Since Last Earnings Report? | Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? | Zacks Investment Research | 2025-12-03 12:36:15 |
| Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript | Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript | Seeking Alpha | 2025-12-03 11:33:26 |
| Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock? | VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum. | Zacks Investment Research | 2025-12-03 10:06:12 |
| 2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term | Alphabet's advertising, cloud, and AI businesses are booming. Vertex is branching out beyond its still-successful core business. | The Motley Fool | 2025-12-03 06:15:00 |
| 3 Top Stocks to Buy in December | MercadoLibre has tremendous potential in the Latin American e-commerce and fintech markets. TransMedics Group is preparing to expand into Italy and has plenty of room to grow in the U.S. as well. | The Motley Fool | 2025-12-01 19:45:00 |
| Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock | Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. | Zacks Investment Research | 2025-12-01 10:01:32 |
| BLI Banque de Luxembourg Investments Purchases Shares of 6,500 Vertex Pharmaceuticals Incorporated $VRTX | BLI Banque de Luxembourg Investments acquired a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 6,500 shares of the pharmaceutical company's stock, valued at approximately $2,868,000. Several other hedge funds | Defense World | 2025-12-01 03:28:59 |
| Where Will Vertex Pharmaceuticals Be in 5 Years | Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets beyond CF. | The Motley Fool | 2025-11-27 06:31:00 |
| AXQ Capital LP Purchases Shares of 484 Vertex Pharmaceuticals Incorporated $VRTX | AXQ Capital LP acquired a new position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 484 shares of the pharmaceutical company's stock, valued at approximately $215,000. A number of other institutional investors | Defense World | 2025-11-26 04:32:54 |
| Advisors Asset Management Inc. Has $11.17 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX | Advisors Asset Management Inc. reduced its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 9.6% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,085 shares of the pharmaceutical company's stock after selling 2,659 shares during the quarter. | Defense World | 2025-11-25 04:12:43 |
| Bank Julius Baer & Co. Ltd Zurich Has $148,000 Position in Vertex Pharmaceuticals Incorporated $VRTX | Bank Julius Baer and Co. Ltd Zurich cut its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 8.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 331,910 shares of the pharmaceutical company's stock after selling 30,997 shares during the quarter. | Defense World | 2025-11-25 03:36:45 |
| Elfun Trusts Significantly Reduces Stake in Broadcom Inc by 60.7% | Exploring Elfun Trusts (Trades, Portfolio)' Strategic Moves in Q3 2025 Elfun Trusts (Trades, Portfolio) recently submitted its N-PORT filing for the third quar | GuruFocus | 2025-11-24 12:00:00 |
| Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3 | BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in Citi's 2025 Global Healthcare Conference. Charlie Wagner, Chief Operating and Financial Officer, and David Altshuler, Chief Scientific Officer, will participate in a fireside chat on Wednesday, December 3, 2025, at 9:00 a.m. ET. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Even. | Business Wire | 2025-11-19 16:00:00 |
| Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know | Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. | Zacks Investment Research | 2025-11-18 10:02:24 |
| Columbia Contrarian Core Fund Q3 2025 Performance Review | The fund underperformed its benchmark, the Russell 1000 Index, during the third quarter. Videogame producer Electronic Art's was the top contributor during the period. Elevance Health was the top underperformer over the period. | Seeking Alpha | 2025-11-18 06:40:00 |
| Vertex Pharmaceuticals Incorporated $VRTX Stake Reduced by Bridger Management LLC | Bridger Management LLC lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 54.3% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,778 shares of the pharmaceutical company's stock after selling 22,272 shares during the period. Vertex Pharmaceuticals | Defense World | 2025-11-18 03:51:10 |
| 3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List | The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in the Russell 1000 universe with positive recent consensus revisions to 2026 EPS estimates and that trade at attractive valuations. Goldman sees "more opportunity for alpha than beta" as wide return dispersion and increasing M&A activity in healthcare may favor selected winners. | Seeking Alpha | 2025-11-17 16:05:39 |
| PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors | The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Stock selection within biotechnology and health care providers & services, along with an overweight to biotechnology and an underweight to medtech added the most value relative to the Index. Security selection within medtech, life sciences tools & services, and pharmaceuticals detracted from relative results during the period. | Seeking Alpha | 2025-11-16 14:31:00 |
| My 3 Favorite Stocks to Buy Right Now | Amazon has formidable moats and multiple avenues for growth. Enbridge offers stability, a generous dividend, and growth opportunities related to AI. | The Motley Fool | 2025-11-16 09:30:00 |
| Alger Weatherbie Specialized Growth Fund Q3 2025 Portfolio Update | Class A shares of the Alger Weatherbie Specialized Growth Fund underperformed the Russell 2500 Growth Index during the third quarter of 2025. Semtech Corporation (SMTC), Impinj Inc. (PI), and Artivion, Inc. (AORT) were among the top contributors to performance. SPS Commerce, Inc. (SPSC), Palomar Holdings, Inc. (PLMR), and Vertex, Inc. (VRTX) were among the top detractors from performance. | Seeking Alpha | 2025-11-12 05:09:00 |
| Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Healthcare Conference 2025 Transcript | Vertex Pharmaceuticals Incorporated ( VRTX ) UBS Global Healthcare Conference 2025 November 11, 2025 10:15 AM EST Company Participants Reshma Kewalramani - CEO, President & Director Conference Call Participants Dina Elmonshed Presentation Dina Elmonshed Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. | Seeking Alpha | 2025-11-11 14:41:31 |
| Vertex Pharmaceuticals Incorporated (VRTX) Discusses Updated Data for Pove in IgAN and pMN and Developments in Kidney Disease Portfolio Transcript | Vertex Pharmaceuticals Incorporated ( VRTX ) Discusses Updated Data for Pove in IgAN and pMN and Developments in Kidney Disease Portfolio November 8, 2025 8:00 PM EST Company Participants Susie Lisa - Senior Vice President of Investor Relations Reshma Kewalramani - CEO, President & Director Conference Call Participants James A. Tumlin Richard Lafayette Brad Rovin Carter Gould - Cantor Fitzgerald & Co., Research Division Adam Ferrari - JPMorgan Chase & Co, Research Division Sadia Rahman - Wells Fargo Securities, LLC, Research Division Ananda Ghosh - H.C. | Seeking Alpha | 2025-11-09 01:16:06 |
| Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week | BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove is the on. | Business Wire | 2025-11-08 17:15:00 |
| Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know | Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. | Zacks Investment Research | 2025-11-07 10:00:42 |
| Artisan Global Opportunities Fund Q3 2025 Portfolio Update | During the quarter, we initiated new positions in Spotify, L3Harris Technologies and Insmed. We also added to 3i Group, West Pharmaceutical and Amazon during the quarter. We ended our investment campaigns in Atlassian, Adidas and Vertex Pharmaceuticals during the quarter. | Seeking Alpha | 2025-11-06 08:10:00 |
| VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve? | VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. | Zacks Investment Research | 2025-11-05 12:36:05 |
| Committee stocks on the move: Uber and Vertex Pharma | The Investment Committee discuss some of their stocks on the move today. | CNBC Television | 2025-11-04 13:22:44 |
| Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint | VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint. | Zacks Investment Research | 2025-11-04 11:46:06 |
| Columbia Balanced Fund Q3 2025 Portfolio Update | Electronic Arts' shares outperformed the broader market during the period, driven by renewed investor confidence and momentum surrounding several high-profile product announcements. eBay's shares surged after reporting a strong second-quarter earnings report, bolstering confidence in the company's position in the marketplace. Elevance Health was the top underperformer over the period. Much of the decline through the period was in response to the company's second-quarter earnings announcement. | Seeking Alpha | 2025-11-04 02:30:00 |
| Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates | Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.8 per share, beating the Zacks Consensus Estimate of $4.55 per share. This compares to earnings of $4.38 per share a year ago. | Zacks Investment Research | 2025-11-03 23:58:59 |
| Vertex (VRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates | Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. | Zacks Investment Research | 2025-11-03 23:58:44 |
| Vertex Pharmaceuticals Incorporated (VRTX) Q3 2025 Earnings Call Transcript | Vertex Pharmaceuticals Incorporated ( VRTX ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Susie Lisa - Senior Vice President of Investor Relations Reshma Kewalramani - CEO, President & Director Stuart Arbuckle Charles Wagner - Executive VP, COO & CFO Duncan J. McKechnie - Chief Commercial Officer, Head of North America Commercial & Executive VP Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Evan Seigerman - BMO Capital Markets Equity Research Tazeen Ahmad - BofA Securities, Research Division Brian Abrahams - RBC Capital Markets, Research Division Terence Flynn Philip Nadeau - TD Cowen, Research Division Huidong Wang - Barclays Bank PLC, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division William Pickering - Sanford C. | Seeking Alpha | 2025-11-03 22:06:25 |
| Vertex beats quarterly estimates on cystic fibrosis demand, new drugs | Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer medicines. | Reuters | 2025-11-03 16:20:01 |
| Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book | Vertex stock dipped late Monday despite better-than-expected third-quarter metrics and a slight sales guidance boost. | Investors Business Daily | 2025-11-03 16:12:21 |
| Vertex Reports Third Quarter 2025 Financial Results | BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance. “Vertex delivered strong results across the board in the third quarter, extending our leadership in CF, continuing to build global momentum for CASGEVY, and advancing the launch of JOURNAVX in acute pain,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vert. | Business Wire | 2025-11-03 16:02:00 |
| Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call | Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will release earnings results for the first quarter, after the closing bell on Monday, Nov. 3. | Benzinga | 2025-11-03 14:23:32 |
| 2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon | A former pandemic favorite and a lesser-known biopharmaceutical stock both have value to add to a long-term investor's portfolio. Pfizer's growth has slowed from a few years ago, but its tepid stock price is not telling the whole story of this innovative company. | The Motley Fool | 2025-11-03 07:37:00 |
| Inflation-Proof Investing: Which Growth Stock Will Double Your Money in 6 Years? | Netflix and Vertex benefit from strong pricing power that could come in handy if inflation increases. Both companies are leaders in their niche with excellent growth prospects. | The Motley Fool | 2025-11-03 07:00:00 |
| My Top Growth Stock to Buy in November | Vertex Pharmaceuticals has three key ways to deliver strong growth. Two factors about the biotech company are especially comforting. | The Motley Fool | 2025-11-02 16:44:00 |
| Top Biotech Stocks To Keep An Eye On – October 28th | Danaher, argenex, Recursion Pharmaceuticals, Vertex Pharmaceuticals, and Medpace are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that research, develop, and commercialize biological medicines, diagnostics, and related technologies, often focused on drug discovery, clinical trials, and regulatory approvals. For investors they tend to be | Defense World | 2025-10-30 02:15:26 |
| Exploring Analyst Estimates for Vertex (VRTX) Q3 Earnings, Beyond Revenue and EPS | Get a deeper insight into the potential performance of Vertex (VRTX) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics. | Zacks Investment Research | 2025-10-29 10:16:12 |
| Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? | Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform in the third quarter. | Zacks Investment Research | 2025-10-28 12:56:06 |
| Vertex to Participate in the UBS Global Healthcare Conference on November 11 | BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the UBS Global Healthcare Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, November 11, 2025, at 10:15 a.m. ET. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast wil. | Business Wire | 2025-10-27 16:00:00 |
| Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? | Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | Zacks Investment Research | 2025-10-27 11:06:12 |
| These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar | The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now. | Zacks Investment Research | 2025-10-27 09:51:05 |
| Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030 | Pfizer is racing towards patent cliffs that will lead to even worse financial results. Vertex Pharmaceuticals is posting strong revenue growth and excellent clinical progress. | The Motley Fool | 2025-10-27 05:43:00 |
| The Best Stocks to Invest $50,000 In Right Now | Google parent Alphabet is well-positioned to win in the AI, cloud, robotaxi, and quantum computing markets. Dominion Energy is a backdoor AI play with a stable business and juicy dividend. | The Motley Fool | 2025-10-24 04:44:00 |
| Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference | BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company's most recently approved medicine, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), at the North American Cystic Fibrosis Conference (NACFC) held from October 22-25 in Seattle, Washington. Several of the abstracts that will be presented at this year's conference demonstrate. | Business Wire | 2025-10-23 09:00:00 |
| Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It | Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store. | Zacks Investment Research | 2025-10-22 10:00:22 |
| Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week | BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential. | Business Wire | 2025-10-17 09:04:00 |
| 2 Unstoppable Growth Stocks to Buy During a Market Crash | President Trump recently reminded investors that it doesn't take much to send a buoyant stock market reeling. When the market opened on Friday, Oct. 10, 2025, the Nasdaq Composite (^IXIC -0.76%) index traded above $23,100 for the first time. | The Motley Fool | 2025-10-15 04:33:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-01-09 | 2026-01-09 | View Filing |
| 4 | 2026-01-08 | 2026-01-08 | View Filing |
| 4 | 2025-12-05 | 2025-12-05 | View Filing |
| 4 | 2025-12-05 | 2025-12-05 | View Filing |
| 4 | 2025-12-05 | 2025-12-05 | View Filing |
| 4 | 2025-12-05 | 2025-12-05 | View Filing |
| 4 | 2025-11-20 | 2025-11-20 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| 4 | 2025-11-17 | 2025-11-17 | View Filing |
| 10-Q | 2025-11-04 | 2025-11-04 | View Filing |
| 8-K | 2025-11-03 | 2025-11-03 | View Filing |
| 4 | 2025-10-17 | 2025-10-17 | View Filing |
| 4 | 2025-10-17 | 2025-10-17 | View Filing |
| 4 | 2025-10-03 | 2025-10-03 | View Filing |
| 4 | 2025-08-29 | 2025-08-29 | View Filing |
| 4 | 2025-08-07 | 2025-08-07 | View Filing |
| 4 | 2025-08-07 | 2025-08-07 | View Filing |
| 10-Q | 2025-08-05 | 2025-08-05 | View Filing |
| 8-K | 2025-08-04 | 2025-08-04 | View Filing |
| 4 | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-07-17 | 2025-07-17 | View Filing |
| 3 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-05-19 | 2025-05-19 | View Filing |
| 8-K | 2025-05-19 | 2025-05-19 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| SC 13G | 2025-05-13 | 2025-05-13 | View Filing |
| 10-Q | 2025-05-06 | 2025-05-06 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 8-K | 2025-05-05 | 2025-05-05 | View Filing |
| 4 | 2025-04-17 | 2025-04-17 | View Filing |
| 4 | 2025-04-17 | 2025-04-17 | View Filing |
| ARS | 2025-04-03 | 2025-04-03 | View Filing |
| DEFA14A | 2025-04-03 | 2025-04-03 | View Filing |
| DEF 14A | 2025-04-03 | 2025-04-03 | View Filing |
| 8-K | 2025-03-28 | 2025-03-28 | View Filing |
| 4 | 2025-03-17 | 2025-03-17 | View Filing |
| 4 | 2025-03-12 | 2025-03-12 | View Filing |
| 4 | 2025-03-12 | 2025-03-12 | View Filing |
| 4 | 2025-03-12 | 2025-03-12 | View Filing |
| 4 | 2025-03-06 | 2025-03-06 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-24 | 2025-02-24 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| S-3ASR | 2025-02-13 | 2025-02-13 | View Filing |
| SC 13G/A | 2025-02-13 | 2025-02-13 | View Filing |
| 10-K | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-12 | 2025-02-12 | View Filing |
| 4 | 2025-02-12 | 2025-02-12 | View Filing |
| 4 | 2025-02-12 | 2025-02-12 | View Filing |
| 4 | 2025-02-12 | 2025-02-12 | View Filing |
| 4 | 2025-02-12 | 2025-02-12 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Williams PercentR Strategy | 30.54% | 1 | 817 | 0.02 | 0.09 | 25.95 |
| Larry Williams PercentR Strategy | 24.26% | 1 | 434 | 0.01 | 0.1 | 19.67 |
| Keltner Channel Strategy | 21.43% | 1.02 | 256 | 0.01 | 0.07 | 16.84 |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxxx | xxxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xxxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxx |
| xxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxx | xxx |
| xxxxxxxxxxxxx | xxxxxx% | x | xxxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | x | xxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |